39th Annual Meeting Call for Abstracts
Chicago, IL | September 25-28, 2024
Submission deadline: Monday, February 5, 2024 (11:59 PM CDT)
Acceptance notifications sent on or before: early April 2024
Instructions for submission
- To begin your proposal, click the Submit button located at the bottom of this page.
- You do not have to be a NASS member to submit an abstract or proposal.
- You will be redirected to the NASS login page to begin your submission
- Use your NASS username (email address) and password to login. Forgotten passwords can be requested from the NASS log-in page. If this is your first interaction with NASS, you can create a new account on the login page
- All co-authors must submit current disclosure. Any author with an out-of-date disclosure will not be allowed to be added to the abstract; please have them update their disclosure before submitting. Submit/update disclosure here.
Contact NASS Education at education@spine.org with questions.
Required Information for Abstracts
| 1. Title | |
| 2. Category | |
|
Basic Science/Biologics
|
Manual Therapy
|
|
Biomechanics
|
Motion Preservation
|
|
Complications
|
Psychosocial/Behavioral
|
|
Diagnostics/Imaging
|
Socioeconomics/Industrial/Ergonomics
|
|
Epidemiology/Etiology
|
Spinal Deformity
|
|
Exercise
|
Surgery-Cervical
|
|
Injections/Interventions
|
Surgery-Thoracolumbar
|
|
Interdisciplinary Care
|
Trauma
|
| 3. Keywords (Optional, Maximum of 3) | |
| 4. FDA Device/Drug Status | |
|
If a device or drug requiring FDA approval is identified as an important component of your presentation, you must indicate the FDA status for the use as discussed in your presentation. You will be required to provide the name of the device(s) and/or drug(s) in your presentation requiring FDA approval, along with the status of Approved, Investigational/Not Approved for use as discussed in the presentation, or Study conducted outside the US/not intended for submission to the FDA.
This information will be listed in the meeting’s Final Program and in The Spine JournalTM Meeting Proceedings Supplement.
|
|
| 5. Prior/Future Presentation | |
|
Has this material been presented within the last 12 months or been accepted for publication within the next year?
If yes, please note the meeting and the year during which it was or will be presented.
|
|
| 6. Abstract Entry | |
|
The character limit cannot exceed 3,500. Punctuation and spaces count as characters.
Presenters may not use their abstract/proposal to market products or services. Use product-based names only when necessary. Use generic names wherever possible.
Available Fields: Background Context, Purpose, Study Design/Setting, Patient Sample, Outcome Measures, Methods, Results, Conclusions
|
|
| 7. Authors | |
|
An author must have a record in the NASS database to be added to an abstract. To create a record, visit any NASS log-in page and click “Sign Up as New Contact.” Each record must have a unique email address associated.
IMPORTANT: All authors must have disclosure submitted under their unique records to finalize submission at www.spine.org/disclosure. If you are unable to secure disclosure, remove the author from the abstract and submit. Authors can be added later, as long as disclosure has been submitted.
PLEASE NOTE: Please make sure the order in which you list the authors is accurate to how you would like it to appear in publications. If you wish to add or remove authors from the author list after the submission deadline, please email education@spine.org.
|
|
General Submission Policies
- Each author must submit disclosure under his/her record within one year of the abstract submission deadline, using a unique email address/password. If disclosure is not possible by the deadline, please remove the author from your abstract and submit. Authors may be added after abstract acceptance, if disclosure has been submitted within the acceptable timeframe.
- Prior to submitting your abstract(s), please ensure you and/or one of your team of authors has secured proper funding sources in order to present at the meeting. Presenting authors of all accepted abstracts must register for the meeting and are responsible for their own travel expenses as well as the meeting registration fee.
- NASS reserves the right to withdraw a proposal at any time.
- All presenters must adhere to the AMA Code of Medical Ethics, Opinion 8.061, “Gifts to Physicians from Industry.” More information may be found at https://journalofethics.ama-assn.org/article/ama-code-medical-ethics-opinions-physicians-relationships-drug-companies-and-duty-assist-containing/2014-04. Medical device companies are prohibited from submitting abstracts on behalf of the author(s). Violations subverting the educational content of the meeting and threatening NASS’ ACCME accreditation will be subject to disciplinary action.
- Presenters may not use their presentation to market products or services. Use generic names wherever possible. Use product-based names only when necessary.
Contact the NASS Education Department at education@spine.org with questions.